Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine

(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection; (2) Methods: We evaluated anti S-RBD IgG levels by indirect c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diagnostics (Basel) Ročník 11; číslo 7; s. 1135
Hlavní autoři: Lo Sasso, Bruna, Giglio, Rosaria Vincenza, Vidali, Matteo, Scazzone, Concetta, Bivona, Giulia, Gambino, Caterina Maria, Ciaccio, Anna Maria, Agnello, Luisa, Ciaccio, Marcello
Médium: Journal Article
Jazyk:angličtina
Vydáno: Basel MDPI AG 22.06.2021
MDPI
Témata:
Age
Antibodies
Asymptomatic
Coronaviruses
COVID-19
COVID-19 vaccines
Immunization
immunosurvelliance
Infections
Proteins
S-RBD IgG
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
spike
ISSN:2075-4418, 2075-4418
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection; (2) Methods: We evaluated anti S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 2248 vaccinated subjects without previous SARS-CoV-2 infection, 91 vaccinated individuals recovered from COVID-19, and 268 individuals recovered from COVID-19 who had not been vaccinated. Among those who were healthy and vaccinated, 352 subjects performed a re-dosing after about 72 days from the first measurement. (3) Results: Anti S-RBD IgG levels were lower in subjects with previous infection than vaccinated subjects, with or without previous infection (p < 0.001). No difference was observed between vaccinated subjects, with and without previous SARS-CoV-2 infection. Overall, anti-RBD IgG levels were higher in females than males (2110 vs. 1341 BAU/mL; p < 0.001) as well as in subjects with symptoms after vaccination than asymptomatic ones (2085 vs. 1332 BAU/mL; p = 0.001) and lower in older than younger subjects. Finally, a significant decrease in anti-RBD IgG levels was observed within a short period from a complete two-dose cycle vaccination. (4) Conclusions: Our results show an efficacy antibody response after vaccination with age-, time- and sex-related differences.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics11071135